$RGNX

Mizuho initiated Regenxbio with an Outperform rating, citing strong approval potential for its pipeline drugs targeting Duchenne muscular dystrophy, wet age-related macular degeneration, and diabetic retinopathy. The firm set a $22 price target, implying 196% upside.

Mizuho initiated coverage on Regenxbio (NASDAQ:RGNX) with an outperform rating and $22.00 price target, citing its gene therapy pipeline. The stock is down 48% YTD. FDA placed a clinical hold on RGX-121, but the company reported positive Phase 2 data for diabetic retinopathy. Insider buying was also noted.

Three gene therapy programs for neovascular age-related macular degeneration (nAMD) are nearing phase 3 readouts. AbbVie and REGENXBIO's sura-vec (sura-vec) expects phase 3 results by late 2026. 4D Molecular Therapeutics' 4D-150 (4D-150) phase 3 trials are fully enrolled, with results expected in 2027. Adverum Biotechnologies' ixoberogene soroparvovec (ixo-vec) is in phase 3, with one trial fully enrolled.

Regenxbio (RGNX) stock rose 3.5% in pre-market trading after presenting positive three-year data from its Phase II ALTITUDE study. 60% of participants showed clinically meaningful improvement, with no adverse events. Stifel maintained a Buy rating with a $42 price target. The broader market was modestly positive, but Regenxbio's pipeline developments drove the move.

Regenxbio Inc (RGNX) shares rose 4.8% premarket after presenting positive 3-year data for its gene therapy, surabgene lomparvovec, in diabetic retinopathy. The study showed sustained improvement without additional treatment. The company also settled patent litigation with Sarepta Therapeutics for $39.0 million.

Nasdaq and S&P 500 futures rose despite surging Treasury yields. Akamai (AKAM) surged 20% after a $11.6B deal with Anthropic. Tesla (TSLA) trended upward following a next-gen Roadster unveil and Semi truck production news. SpaceX (SPCX) gained on AI model predictions. Bloom Energy (BE) rose 1% after reaffirming Oracle's (ORCL) fuel-cell contract. Comcast (CMCSA) fell on analyst downgrades. Regenxbio (RGNX) rose 2% on positive gene therapy data.

REGENXBIO (Nasdaq: RGNX) presented positive three-year data from its Phase II ALTITUDE study of surabgene lomparvovec for diabetic retinopathy at the Retina Society Annual Meeting. The data showed durable efficacy with 60% of participants achieving a >2-step improvement on the DRSS. No new safety signals were observed. The company is advancing the treatment in a Phase IIb/III trial.

REGENXBIO Inc. (RGNX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 23, 2026, REGENXBIO Inc. (the “Company”) and The Trustees of the University of Pennsylvania (“UPenn”) entered into a Settlement Agreement (the “Settlement Agreement”) with Sarepta Therapeutics, Inc. and Sarepta T

The FDA is scrutinizing REGENXBIO's RGX-202 and Solid Biosciences' SGT-003, both Duchenne muscular dystrophy treatments, for accelerated approval. The FDA requires evidence that microdystrophin expression predicts clinical benefit, citing Pfizer's failed CIFFREO trial as a cautionary example. REGENXBIO reported 93% of patients reached 10% microdystrophin expression, but functional data is limited. The FDA seeks robust evidence before approval, given the permanent nature of gene therapy.

Six Montgomery County companies raised over $566 million in Q3. Forbright (Nasdaq) completed an IPO, raising $142.2 million. Xometry (Nasdaq) announced a $225 million secondary offering. RegenxBio (Nasdaq) raised $90.04 million in a public offering. Georgiamune secured $92.69 million in venture funding. Arculus Solutions raised $1.95 million in Seed-1 funding. Jesse & Ben raised $15 million in Series A funding.